Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Immutep Ltd (YP1B) Stock Price & Analysis

0 Followers

YP1B Stock Chart & Stats

€0.01-€0.00(-13.33%)
At close: 5:30 PM GMT+1
€0.015€0.02€0.025Sep 15Nov 10
Day’s Range
EUR 0.01 - EUR 0.04
52-Week Range
EUR 0.01 - EUR 0.25
Previous Close
EUR 0.02
Volume
N/A
Average Volume (3M)
1,186
Market Cap
EUR 21.81M
Enterprise Value
EUR 10.28M
Total Cash (Recent Filing)
EUR 68.87M
Total Debt (Recent Filing)
EUR 1.05M
Price to Earnings (P/E)
―
Beta
3.11
Next Earnings
Feb 25, 2027 (Est.)
EPS Estimate
-0.01
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue And Gross Margin Improvement

The sharp FY2026 revenue increase indicates improving commercial traction, while the approximately 83% gross margin shows that growth can generate meaningful gross profit. If sustained, this combination could improve operating leverage and provide a stronger foundation for funding the pipeline over time.

Low Financial Leverage

Very low debt and a modest interest burden reduce balance-sheet pressure while the company advances its clinical programs. Positive equity provides some capital buffer, giving management greater flexibility than a highly leveraged biotechnology company during ongoing development and commercialization efforts.

Pipeline Expansion Into Autoimmune Disease

The IMP761 Phase I update expands the strategic potential of Immutep’s LAG-3 platform beyond oncology into autoimmune disease. Although early-stage, evidence from a controlled first-in-human study supports continued platform development and could create additional long-term partnering or product opportunities.

Bears Say

Persistent Large Net Losses

The company remains far from profitability despite stronger revenue and gross margin. A net loss of roughly $79.3M indicates that operating expenses continue to substantially exceed gross profit, making future earnings dependent on successful clinical progress, commercial scale, or additional financing.

Material Operating Cash Burn

Sustained negative operating and free cash flow means Immutep is consuming capital rather than internally funding its operations and clinical pipeline. Continued cash burn can reduce strategic flexibility and increase reliance on external funding until revenue growth and operating scale are sufficient to support development costs.

Erosion Of Equity Base

The substantial decline in equity reflects the financial impact of ongoing losses and weak returns on equity. Even with limited debt, a shrinking capital base increases the importance of future financing capacity and raises the possibility that continued losses could lead to shareholder dilution or constrained investment.

Immutep Ltd News

YP1B FAQ

What was Immutep Ltd’s price range in the past 12 months?
Immutep Ltd lowest stock price was €0.01 and its highest was €0.25 in the past 12 months.
What is Immutep Ltd’s market cap?
Immutep Ltd’s market cap is €21.81M.
When is Immutep Ltd’s upcoming earnings report date?
Immutep Ltd’s next earnings report is estimated for Feb 25, 2027 (not yet confirmed), which is in 105 days.
How were Immutep Ltd’s earnings last quarter?
Immutep Ltd released its earnings results on Sep 02, 2026. The company reported -€0.014 earnings per share for the quarter, missing the consensus estimate of -€0.003 by -€0.012.
Is Immutep Ltd overvalued?
According to Wall Street analysts Immutep Ltd’s price is currently Undervalued.
Does Immutep Ltd pay dividends?
Immutep Ltd does not currently pay dividends.
What is Immutep Ltd’s EPS estimate?
Immutep Ltd’s EPS estimate is -0.01.
How many shares outstanding does Immutep Ltd have?
Immutep Ltd has 1,474,110,200 shares outstanding.
What happened to Immutep Ltd’s price movement after its last earnings report?
Immutep Ltd reported an EPS of -€0.014 in its last earnings report, missing expectations of -€0.003. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Immutep Ltd?
Currently, no hedge funds are holding shares in DE:YP1B
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology